Genenta Science (GNTA) Competitors $5.00 +0.30 (+6.38%) (As of 10:30 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GNTA vs. VALN, DNA, CTNM, AMLX, ALEC, KMDA, QTTB, BTMD, JSPR, and ACIUShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Valneva (VALN), Ginkgo Bioworks (DNA), Contineum Therapeutics (CTNM), Amylyx Pharmaceuticals (AMLX), Alector (ALEC), Kamada (KMDA), Q32 Bio (QTTB), biote (BTMD), Jasper Therapeutics (JSPR), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Valneva Ginkgo Bioworks Contineum Therapeutics Amylyx Pharmaceuticals Alector Kamada Q32 Bio biote Jasper Therapeutics AC Immune Valneva (NASDAQ:VALN) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking. Does the MarketBeat Community believe in VALN or GNTA? Valneva received 25 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 60.38% of users gave Valneva an outperform vote. CompanyUnderperformOutperformValnevaOutperform Votes3260.38% Underperform Votes2139.62% Genenta ScienceOutperform Votes787.50% Underperform Votes112.50% Do analysts recommend VALN or GNTA? Valneva currently has a consensus target price of $18.50, suggesting a potential upside of 313.87%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 400.00%. Given Genenta Science's higher probable upside, analysts plainly believe Genenta Science is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer VALN or GNTA? In the previous week, Valneva had 2 more articles in the media than Genenta Science. MarketBeat recorded 4 mentions for Valneva and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.00 beat Valneva's score of -0.04 indicating that Genenta Science is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, VALN or GNTA? Valneva has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Do institutionals & insiders have more ownership in VALN or GNTA? 11.4% of Valneva shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is VALN or GNTA more profitable? Genenta Science has a net margin of 0.00% compared to Valneva's net margin of -4.35%. Genenta Science's return on equity of 0.00% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-4.35% -3.93% -1.42% Genenta Science N/A N/A N/A Which has higher valuation and earnings, VALN or GNTA? Genenta Science has lower revenue, but higher earnings than Valneva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$165.52M2.19-$109.78M-$0.13-34.38Genenta ScienceN/AN/A-$12.60MN/AN/A SummaryGenenta Science beats Valneva on 9 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.35M$2.93B$5.04B$8.81BDividend YieldN/A1.89%5.16%4.07%P/E RatioN/A46.01130.5317.82Price / SalesN/A360.251,183.8674.55Price / CashN/A160.0933.6132.53Price / Book3.883.734.684.68Net Income-$12.60M-$41.63M$119.23M$226.08M7 Day Performance-3.89%-4.73%-1.83%-1.04%1 Month Performance-12.15%-6.53%-3.61%1.04%1 Year Performance-13.76%25.63%31.74%26.28% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.3777 of 5 stars$5.00+6.4%$25.00+400.0%-13.8%$91.45MN/A0.007News CoverageGap UpVALNValneva2.2966 of 5 stars$4.47-4.3%$18.50+313.9%-62.1%$363.19M$165.52M0.00700Gap DownDNAGinkgo Bioworks1.1366 of 5 stars$6.44+1.3%$4.58-29.0%N/A$357.94M$251.46M0.001,218Short Interest ↓CTNMContineum Therapeutics1.6433 of 5 stars$13.70+0.4%$29.25+113.5%N/A$353.19M$50M0.0031AMLXAmylyx Pharmaceuticals4.3626 of 5 stars$5.12-2.1%$11.43+123.2%-59.5%$350.98M$380.79M0.00200Analyst UpgradeALECAlector4.3736 of 5 stars$3.55-2.2%$20.67+482.2%-26.1%$347.65M$97.06M-2.14270Positive NewsKMDAKamada3.8063 of 5 stars$5.86+0.7%$14.50+147.4%+23.3%$336.83M$142.52M20.79360Analyst RevisionQTTBQ32 Bio1.6142 of 5 stars$27.24-0.1%$72.33+165.5%N/A$331.78M$1.16M0.0039BTMDbiote3.1975 of 5 stars$5.92-2.3%$8.39+41.7%+19.8%$320.98M$185.36M23.31194JSPRJasper Therapeutics2.6633 of 5 stars$21.06+0.4%$74.86+255.4%+227.3%$315.90MN/A0.0020ACIUAC Immune2.3118 of 5 stars$3.19-1.5%$12.00+276.2%+0.0%$315.62M$16.48M0.00140Positive News Related Companies and Tools Related Companies Valneva Competitors Ginkgo Bioworks Competitors Contineum Therapeutics Competitors Amylyx Pharmaceuticals Competitors Alector Competitors Kamada Competitors Q32 Bio Competitors biote Competitors Jasper Therapeutics Competitors AC Immune Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNTA Stock Alerts